PIK3CA mutation

MINNEAPOLIS, Minnesota, USA , June 2, 2026 Celcuity has announced groundbreaking results from the Phase 3 VIKTORIA-1 clinical trial,...

MINNEAPOLIS, MINNESOTA, May 01, 2026 Celcuity has announced positive topline results from its Phase 3 VIKTORIA-1 trial, demonstrating a...

BASEL, Switzerland, March 20, 2026 Novartis announced a major strategic acquisition to strengthen its oncology portfolio, agreeing to acquire...